Seres Therapeutics, Inc.

NasdaqGS:MCRB Stock Report

Market Cap: US$139.8m

Seres Therapeutics Future Growth

Future criteria checks 0/6

Seres Therapeutics's revenue and earnings are forecast to decline at 121.4% and 117.1% per annum respectively while EPS is expected to decline by 118.4% per annum.

Key information

-117.1%

Earnings growth rate

-118.45%

EPS growth rate

Biotechs earnings growth23.1%
Revenue growth rate-121.4%
Future return on equityn/a
Analyst coverage

Low

Last updated05 Dec 2025

Recent future growth updates

Recent updates

Seres Therapeutics: Speculative Gem Backed By SER‑155 FDA Breakthrough

Jul 29

Little Excitement Around Seres Therapeutics, Inc.'s (NASDAQ:MCRB) Revenues As Shares Take 30% Pounding

Nov 15
Little Excitement Around Seres Therapeutics, Inc.'s (NASDAQ:MCRB) Revenues As Shares Take 30% Pounding

Seres Therapeutics' Strategic Sale Of Vowst Warrants A Rating Upgrade

Sep 23

Seres Therapeutics, Inc. (NASDAQ:MCRB) Shares Fly 44% But Investors Aren't Buying For Growth

Jul 13
Seres Therapeutics, Inc. (NASDAQ:MCRB) Shares Fly 44% But Investors Aren't Buying For Growth

Seres Therapeutics, Inc. (NASDAQ:MCRB) Shares Fly 46% But Investors Aren't Buying For Growth

May 08
Seres Therapeutics, Inc. (NASDAQ:MCRB) Shares Fly 46% But Investors Aren't Buying For Growth

Benign Growth For Seres Therapeutics, Inc. (NASDAQ:MCRB) Underpins Stock's 30% Plummet

Mar 23
Benign Growth For Seres Therapeutics, Inc. (NASDAQ:MCRB) Underpins Stock's 30% Plummet

Seres Therapeutics' Balancing Act: Breakthrough IP And Financing Concerns

Jan 30

Lacklustre Performance Is Driving Seres Therapeutics, Inc.'s (NASDAQ:MCRB) 30% Price Drop

Dec 18
Lacklustre Performance Is Driving Seres Therapeutics, Inc.'s (NASDAQ:MCRB) 30% Price Drop

Lacklustre Performance Is Driving Seres Therapeutics, Inc.'s (NASDAQ:MCRB) 27% Price Drop

Aug 31
Lacklustre Performance Is Driving Seres Therapeutics, Inc.'s (NASDAQ:MCRB) 27% Price Drop

Seres Therapeutics (NASDAQ:MCRB) Has Debt But No Earnings; Should You Worry?

Aug 09
Seres Therapeutics (NASDAQ:MCRB) Has Debt But No Earnings; Should You Worry?

Is Seres Therapeutics (NASDAQ:MCRB) Weighed On By Its Debt Load?

Dec 28
Is Seres Therapeutics (NASDAQ:MCRB) Weighed On By Its Debt Load?

Estimating The Fair Value Of Seres Therapeutics, Inc. (NASDAQ:MCRB)

Sep 01
Estimating The Fair Value Of Seres Therapeutics, Inc. (NASDAQ:MCRB)

Seres Therapeutics: What The Market Is Missing

Aug 19

Seres Therapeutics GAAP EPS of -$0.70 misses by $0.10, revenue of $1.22M

Aug 03

Seres Therapeutics: The Good And The Challenging

Jul 12

Seres Therapeutics stock slips on $100M stock offering

Jun 30

Earnings and Revenue Growth Forecasts

NasdaqGS:MCRB - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2027N/A-104N/A-871
12/31/2026N/A-82N/A-772
12/31/202503N/A53
9/30/202505-23-23N/A
6/30/2025N/A-54-60-60N/A
3/31/2025N/A-60-87-86N/A
12/31/2024N/A-126-149-149N/A
9/30/2024N/A-145-158-157N/A
6/30/2024-126-225-185-182N/A
3/31/20241-152-80-76N/A
12/31/2023N/A-190-125-117N/A
9/30/20231-224-133-123N/A
6/30/2023130-153-133-123N/A
3/31/20235-265-250-239N/A
12/31/2022N/A-184-239-229N/A
9/30/202213-231-236-228N/A
6/30/2022137-103-51-40N/A
3/31/2022141-87-41-30N/A
12/31/2021145-66-37N/A
9/30/2021155-343241N/A
6/30/202130-132-117-113N/A
3/31/202131-105-101-99N/A
12/31/202033-89-94-94N/A
9/30/202023-90-90-90N/A
6/30/202029-76-83-82N/A
3/31/202035-66-69-68N/A
12/31/201935-70-78-77N/A
9/30/201938-73-50-50N/A
6/30/201940-78N/A-55N/A
3/31/201932-95N/A-68N/A
12/31/201828-99N/A-63N/A
9/30/201821-107N/A-96N/A
6/30/201835-92N/A-77N/A
3/31/201833-92N/A-77N/A
12/31/201732-89N/A-76N/A
9/30/201732-86N/A-76N/A
6/30/201722-97N/A-83N/A
3/31/201722-97N/A-83N/A
12/31/201622-92N/A44N/A
9/30/201619-86N/A53N/A
6/30/20166-82N/A53N/A
3/31/20163-67N/A69N/A
12/31/2015N/A-55N/A-41N/A
9/30/2015N/A-44N/A-33N/A
6/30/2015N/A-34N/A-25N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: MCRB's earnings are forecast to decline over the next 3 years (-117.1% per year).

Earnings vs Market: MCRB's earnings are forecast to decline over the next 3 years (-117.1% per year).

High Growth Earnings: MCRB's earnings are forecast to decline over the next 3 years.

Revenue vs Market: MCRB's revenue is expected to decline over the next 3 years (-121.4% per year).

High Growth Revenue: MCRB's revenue is forecast to decline over the next 3 years (-121.4% per year).

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if MCRB's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/01/09 14:25
End of Day Share Price 2026/01/09 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Seres Therapeutics, Inc. is covered by 14 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Tazeen AhmadBofA Global Research
John NewmanCanaccord Genuity
John TannerCantor Fitzgerald & Co.